— Research monograph
AOD-9604
A modified fragment of growth hormone studied for lipolytic activity.
Updated
- Class
- Modified C-terminal fragment of human growth hormone (hGH 176-191 + N-terminal Tyr)
- Half-life (research)
- ~3 hr (preclinical pharmacokinetic data).
- Origin
- Developed at Monash University in the 1990s by Frank Ng and colleagues as a synthetic fragment representing the putative lipolytic domain of human growth hormone.
- Solubility
- Water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures.
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic fragment of human growth hormone, with an additional tyrosine residue at the N-terminus added for stability. It represents one of the most-studied "fragment-of-hormone" approaches in metabolic research.
Preclinical work has investigated whether AOD-9604 retains the lipolytic effects of full-length growth hormone while lacking the growth-promoting and glycemic effects mediated through the GH receptor. The compound has been the subject of human clinical trials for obesity, though it has not received regulatory approval as a therapeutic.
How does AOD-9604 work?
Reported to stimulate lipolysis and inhibit lipogenesis in adipocyte models. The mechanism is proposed to be independent of the canonical GH receptor pathway; specific receptor targets remain incompletely characterized in the public literature.
Research applications
- Lipolysis pathway research
- GH-fragment pharmacology
- Adipocyte metabolism studies
- Cartilage repair preclinical models
AOD-9604 at Merit
Research review on The Assay, Merit’s editorial publication: AOD-9604: What the Obesity Trials Showed
Form & storage
AOD-9604 ships as a sealed, lyophilized (freeze-dried) powder. Water-soluble. Physicochemical context only. Merit Sciences publishes no reconstitution or preparation procedures. Store sealed, light-protected, and follow your institution’s handling procedures for research materials.
Frequently asked questions
What is AOD-9604?
AOD-9604 is a synthetic 16-amino-acid peptide derived from the C-terminal lipolytic fragment of human growth hormone, with an additional tyrosine residue at the N-terminus added for stability. It represents one of the most-studied "fragment-of-hormone" approaches in metabolic research. Merit supplies it as a lyophilized research compound for research use only, not for human or veterinary use.
How does AOD-9604 work?
Reported to stimulate lipolysis and inhibit lipogenesis in adipocyte models. The mechanism is proposed to be independent of the canonical GH receptor pathway; specific receptor targets remain incompletely characterized in the public literature. Mechanistic descriptions summarize published preclinical findings and are not clinical claims.
What is the half-life of AOD-9604?
~3 hr (preclinical pharmacokinetic data). Values reflect preclinical or research-context reports, not clinical pharmacokinetics.
Is Merit AOD-9604 for human use?
No. It is sold strictly for research use only: not for human or veterinary use, and not for diagnostic or therapeutic use.
Is AOD-9604 FDA-approved?
Not approved by the FDA for any use. Supplied for research use only. AOD-9604 is named on the WADA 2026 Prohibited List under S2 as a growth hormone fragment and is prohibited at all times.
How is each batch of AOD-9604 tested?
Every Merit batch is tested by an independent laboratory for identity and HPLC purity before it is listed, and Merit identifies batches by date rather than by lot number. Current certificates: AOD-9604 5 mg, December 2025 batch, 99.897% purity (meritsciences.com/coa/MRT-2512-01).
Regulatory status checked October 22, 2026 against: Drugs@FDA, FDA Category 2 list, WADA Prohibited List.
References
- The effects of human GH and its lipolytic fragment (AOD9604) on lipid metabolism following chronic treatment in obese mice and beta3-AR knock-out mice. Heffernan M, Summers RJ, Thorburn A, et al.. Endocrinology, 2001 · doi:10.1210/en.142.12.5182
- Metabolic studies of a synthetic lipolytic domain (AOD9604) of human growth hormone. Ng FM, Sun J, Sharma L, et al.. Hormone Research, 2000 · PMID 11146367
- Increase of fat oxidation and weight loss in obese mice caused by chronic treatment with human growth hormone or a modified C-terminal fragment. Heffernan MA, Thorburn AW, Fam B, et al.. International Journal of Obesity, 2001 · doi:10.1038/sj.ijo.0801740
For research use only. Not for human or veterinary use. Reference information summarized from published literature, not medical advice.